In the world of pharmaceutical distribution, standing still is not an option. Regulations evolve, expectations sharpen, and the responsibility carried by Responsible Persons (RPs) continues to grow. Maintaining clarity, confidence, and compliance requires more than experience alone – it requires regular refinement.
In the world of pharmaceutical distribution, product recalls aren’t an occasional inconvenience—they’re an operational reality. And when they occur, the expectations on wholesale dealers are high. The MHRA’s guidance is clear: distributors sit at a pivotal junction in the recall process, and their preparedness can determine whether a quality issue stays contained or becomes a national problem.
When quality issues arise in the lifecycle of a medicinal product, the consequences extend far beyond the pharmacy shelf. The MHRA’s latest 2026 guidance on defective medicinal products offers a comprehensive roadmap for managing these events with rigour, transparency, and patient safety at the centre.
This article provides an overview of the recent MHRA update for UKCA conformity assessment for medical devices, with practical insights for regulatory, quality, and executive teams.
Communication from the GPhC regarding Regulatory Concerns Regarding the Supply and Promotion of Weight-Management Medicines – Mounjaro®, Wegovy® and Related GLP-1 Therapies
